Jacopo Sgrignani

17PUBLICATIONS
59CO-AUTHORS
Haematological tumoursMolecular targetsBiologically active moleculesMedical molecular engineering of nucleic acids and proteinsLiquid biopsies
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (17)

|Nov 03, 2026
Aberrant expression of HERV-K envelope in lymphoma represents an opportunity for novel treatments.

|Jun 13, 2025
FYCO1 Peptide Analogs: Design and Characterization of Autophagy Inhibitors as Co-Adjuvants in Taxane Chemotherapy of Prostate Cancer.

Enrico Mario Alessandro Fassi, Roberta Manuela Moretti, Marina Montagnani Marelli

|Feb 25, 2025
New Synthesis and Pharmacological Evaluation of Enantiomerically Pure (R)- and (S)-Methadone Metabolites as N-Methyl-d-aspartate Receptor Antagonists.

Marco Banzato, Alberto Furlan, Patrizia Locatelli

|Oct 07, 2024
PI3Kδ activation, IL-6 overexpression, and CD37 loss cause resistance to naratuximab emtansine in lymphomas.

Alberto J Arribas, Sara Napoli, Eugenio Gaudio

|May 11, 2024
Computational Design of Novel Cyclic Peptides Endowed with Autophagy-Inhibiting Activity on Cancer Cell Lines.

Marco Albani, Enrico Mario Alessandro Fassi, Roberta Manuela Moretti

|Nov 28, 2023
PI3Kδ activation, IL6 over-expression, and CD37 loss cause resistance to the targeting of CD37-positive lymphomas with the antibody-drug conjugate naratuximab emtansine.

Alberto J Arribas, Eugenio Gaudio, Sara Napoli

Pageof 3

Frequent Collaborators

9 joint publications

Giovanni Grazioso

6 joint publications

Enrico Mario Alessandro Fassi

4 joint publications

Andrea Cavalli

3 joint publications

Alberto J Arribas